These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2021.
In the latest trading session, Moderna (MRNA) closed at $168.10, marking a -0.83% move from the previous day.
Quidel (QDEL) closed the most recent trading day at $119.01, moving -0.42% from the previous trading session.
Snowflake Inc. (SNOW) closed the most recent trading day at $231.44, moving +0.02% from the previous trading session.
These are the communications stocks with the best value, fastest growth, and most momentum for May 2021.
- Investor's Business Daily
MGM Resorts says BetMGM is on track to grab up to 25% market share long-term and rake in $1 billion net revenue by 2022.
- Yahoo Finance
Florida's biggest cannabis company also carries big upside for investors, according to Cowen.
- Investor's Business Daily
Biogen stock tumbled Thursday despite offering a 2021 outlook that still bets on Food and Drug Administration approval for its controversial Alzheimer's treatment known as aducanumab.
While it may not make headlines in the same way oil, gas, and renewable energy do, helium is one of the most important commodities on earth and we could soon be facing a major shortage
Shareholders at Johnson & Johnson approved on a non-binding advisory basis Chief Executive Alex Gorsky's $29.6 million pay plan for 2020 at the healthcare company's annual general meeting on Thursday. The approval was a win for J&J, which faced a "vote no" campaign on its executive pay from the Office of the Illinois State Treasurer, a member of the Investors for Opioid and Pharmaceutical Accountability (IOPA) a coalition which has 61 members with $4.2 trillion in assets under management.
These are the industrial stocks with the best value, fastest growth, and most momentum for May 2021.
These are the consumer staples stocks with the best value, fastest growth, and most momentum for May 2021.
- Yahoo Money
When it comes to a no-brainer retirement investing vehicles, consider the Roth IRA, according to one financial expert.
Dogecoin army’s campaign to drive crypto to $1 was a bust — so why are the bulls feeling vindicated?
It was a dollar or bust for the dogecoin community on Wednesday --- and now it seems as if dogecoin fanatics are just left with the bust. However, a failed attempt at producing an epic rally in doge doesn't seem to have deflated the staunchest supporters of the parody coin.
- Investor's Business Daily
Is AbbVie stock a buy as shares approach a buy point, recovering somewhat after the Food and Drug Administration requested additional data before considering new approvals for Rinvoq?
Indications are, the good times are here, and they are here to stay, at least according to Goldman Sachs global chief strategist Jan Hatzius. As the COVID pandemic crisis fades – thanks to natural immunity and an accelerating vaccination program, the US economy is starting to boom. In Hatzius’ view, the key point is spending. The Biden Administration has come in with strong spending plans, including direct stimulus checks to individuals, and Hatzius sees this as goosing the economy – which is heavily dependent on consumer spending. With spending going up, Hatzius believes it will hold up an expanding economy for 2021. “We have a forecast of very strong growth this year, 7.2% for 2021 GDP growth if you take the annual average, or 8% on a fourth quarter to fourth quarter basis, so that’s very optimistic,” Hatzius noted. Along with strong growth goosed by spend-happy consumers, Goldman Sachs also sees equity markets rising. The investment firm’s stock analysts have been scouring the market, seeking out the stocks that are set to show strong gains in the year ahead, and they have found plenty. Using TipRanks' database, we’ve located two of those Goldman picks, which the firm expects to surge by 50% or better. Let’s take a closer look, find out what else makes them compelling, and hear what the analysts have to say. Hayward Holdings (HAYW) The first Goldman pick we’ll look at, Hayward Holdings, is a leading supplier of swimming pool equipment in the North American market. The company offers, through its subsidiaries, a range of gear for pool maintenance and operations, including cleaners, control systems, filters, heaters, pumps, and valves. Hayward has product lines for both the residential and commercial markets. Last month, Hayward held its IPO, entering the public markets by making over 40 million shares of stock available. Of that total, 22,200,000 shares were offered by the company, with the remainder offered by existing shareholders. The offering was priced at $17, and the company grossed over $377 million in new capital. New investors in the company can expect to get a ‘look under the hood’ on May 5, when Hayward will release its 1Q21 earnings report. The release will be the company’s first as a publicly traded entity, and will cover its last quarter as a private company. For the full year 2020, Hayward saw $875 million in net sales, for a 19% year-over-year gain. Opening up coverage of Hayward for Goldman Sachs, analyst Brian Lee notes that the company has "several favorable attributes," which supports his bullish stance on the stock: "(i) 6%-8% sales CAGR through 2023… (ii) significant exposure to recurring, aftermarket sales with 75% of sales coming from existing pools that require ongoing maintenance, repairs and upgrades… (iii) secular trends supporting greater spending on the pool pad with average equipment spending per pool having doubled over the past 10 years, owing to greater technology advancements... Against this backdrop of solid, stable growth we forecast HAYW to maintain a leading share position given its pricing power and breadth of technology portfolio with industry-leading EBITDA margins in the high-20% range seeing modest expansion through 2023.” In line with these favorable attributes, Lee rates Hayward as a Buy, and his $27 price target implies a 55% upside for the coming year. (To watch Lee’s track record, click here) This newly public stock has already received 8 analyst reviews, and the breakdown is decidedly positive; 7 reviews recommend to Buy while only 1 says to Hold, making the analyst consensus here a Strong Buy. HAYW shares are selling for $17.42 and their $21.14 average price target suggests ~22% one-year upside potential. (See HAYW stock analysis on TipRanks) Diversey Holdings (DSEY) Diversey Holdings lives in a humble economic niche – but one that is essential, especially in these recent times of COVID. Diversey is a provider of hygiene and cleaning products, servicing the food service, food and beverage, healthcare, hospitality, and retail and facility management sectors. The company’s products include cleaning chemicals, floor care machinery, food safety services, and cleaning tools and equipment. We all want to live in clean environments, and Diversey’s contribution to that was worth $2.63 billion in sales last year. The company ran a net loss in both 2019 and 2020, but that loss moderated from $109 million in 2019 to $38.5 million in 2020. Like Hayward above, Diversey is only recently in the public markets. The company’s IPO was held on March 25, just a month ago, with the company making 46.15 million shares available for trading. The IPO was priced at $15 per share. In addition to the shares offered to the public, Diversey announced that the underwriters of the offering ‘exercised their option’ to purchase additional shares. Their purchase added 5 million shares to the total, and put Diversey’s net proceeds at $723 million. Among the fans is Goldman Sachs analyst George Tong, who views Diversey Holdings as a resilient business with share gains, margin improvement and multiple expansion. “We believe DSEY has a resilient business model characterized by recurring revenue streams, sticky customer relationships and essential business solutions. We expect DSEY to realize market share gains to deliver solid average annual top-line growth of 3-4% through 2023 that exceeds growth of the broader industry. Over the medium-to-longer term we see a path for EBITDA margins to expand from 15% to 20% to approach peer group margins, contributing to valuation multiple expansion," Tong opined. These comments back his Buy rating, and his $23 price target shows that he is confident of 51% growth on the one-year time horizon. (To watch Tong’s track record, click here) There are 10 reviews on record for Diversey, and they include 9 Buys and just a single Hold. This makes the consensus rating here a Strong Buy, while the $18.80 average price target implies a ~24% one-year upside for the shares. (See DSEY stock analysis at TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- Investor's Business Daily
Chipmaker Intel late Thursday handily beat Wall Street's first-quarter targets but its second-quarter earnings guidance disappointed. Intel stock dropped in extended trading on the news.
All of these factors create a bullish outlook and might make some investors consider buying strong growth stocks that have yet to fully recover from mid-February's tech and growth selloff...
The company is benefiting from strong demand for personal computers, but sales of its data-center chips were weaker than expected.
- Yahoo Finance
Senate Republicans unveiled a $568 billion counterproposal to President Biden's infrastructure plan.
Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.